Biomarker Discovery and Development
Colon Cancer (CC) Biomarkers
The Advantages of AlfaGene's System ovER cURRENT mETHODOLOGIES
Previous methods of experimentation have utilized malignant
transformed cell lines, isolated
intestinal
epithelial
cells (IECs), and
animal models. In all cases, however, inaccuracies have arisen in
extrapolating from the data obtained from these methods, since each
differs markedly from in vivo
stem and
epithelial cells and each method has inherent limitations (Table 1).
For example, malignant cell lines usually have chromosomal
abnormalities that cause instability. Tumor lines also differ
significantly from the in vivo
cell type being examined, cell line to cell line, and passage to
passage. Transformed cell lines
demonstrate altered growth control due to the transfection of viral
DNA, such as the large T-antigen from SV40. The use
of freshly isolated epithelial or stem cells is often complicated,
not only by the concurrent isolation and contamination with a
mixture of several additional cell types including T cells, B cells,
or macrophages (especially when inflamed tissue is used as cell
source) and low yields, but also, by the fact that the isolation
procedure can alter the phenotype of the cells by cleaving certain
molecules from the cell surface. Furthermore,
surface and crypt epithelial cells may have different phenotypes and
functions and are not usually fully represented in separated
populations. Findings with animal model systems show that
these do not always precisely mimic the functional scenarios of
human intestinal epithelial cells
in vivo.
Table 1. Comparison of previous models of stem and
intestinal
epithelial
cell (IEC) vs. our
newly developed stem, human
intestinal
primary
epithelial
cell (HIPEC), and
human
intestinal
tumorogenic
epithelial
cell (HITEC)
model.
AlfaGene’s technology enables the generation and long-term maintenance in culture of stem and nontransformed primary epithelial cell lines derived from tissue samples, thus avoiding the issues associated with changes induced by transformation, limited yields, and non uniformity.
- Biomarker
Discovery
and Development
- Colon
Cancer
(CC) Biomarkers
- Colorectal Cancer (CRC)
- Opportunity and Potential Impact
- Market Potential
- AlfaGene's Approach
- The Advantages of AlfaGene's System Over Current Methodologies
- Supporting Analysis Data
- Ulcerative Colitis (UC) Biomarkers
- Crohn's Disease (CD) Biomarkers
- Esophageal Cancer (EC) and Barett's Esophagus Biomarkers
- Colon
Cancer
(CC) Biomarkers
- GI Model For Drug Discovery And Development
- Personalized Regenerative Medicine Via Stem Cell Therapy